definiens: means, with respect to a given Calendar Year withrespect to a Licensed Product in any country, that during such Calendar Year, ( x ) one ( 1 ) or more ThirdParties have received Regulatory Marketing Approval to sell in such country a Biosimilar BiologicProduct, ( y ) such Biosimilar Biologic Product(s ) shall be commercially available in such country and(z ) such Biosimilar Biologic Product(s ) shall have, in the aggregate, a [ * * * ] market share of theaggregate of such Licensed Product and Biosimilar Biologic Product(s ) ( based on data provided byIMS International, or if such data is not available, such other reliable data source as reasonablydesignated by [COMPANY] ) as measured by the number of prescriptions . In the event IMS International data(or such other designated data source ) is not sufficient to determine the percentage market share foreach country in the European Union, the percent market share for the European Union countries forwhich data is not available will be deemed to be the average percent market share for those EuropeanUnion countries in which the data * * * Certain information contained herein has been omitted and filed separately with the Securities andExchange Commission . Confidential treatment has been requested with respect to the omitted portions